Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment
Summit Therapeutics Inc. shares rose after it said AstraZeneca Plc would make a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
By John Tozzi · Bloomberg Markets
Summit Therapeutics Inc. shares rose after it said AstraZeneca Plc would make a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.